$49 M

MBRX Mkt cap, 16-Sept-2020
Moleculin Biotech Net income (Q2, 2020)-10.1 M
Moleculin Biotech EBIT (Q2, 2020)-5 M
Moleculin Biotech Cash, 30-Jun-202016.7 M
Moleculin Biotech EV32.4 M

Moleculin Biotech Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

R&D expense

1.5m4.5m9.7m11.0m

General and administrative expense

2.4m4.1m5.2m6.3m

Operating expense total

3.9m8.6m15.0m17.3m

Depreciation and amortization

6.2k18.0k68.0k199.0k

EBIT

(3.9m)(8.7m)(15.0m)(17.5m)

Interest expense

4.0k13.0k

Income tax expense

(229.0k)

Net Income

(3.9m)(9.8m)(11.9m)(13.2m)

Moleculin Biotech Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

5.0m7.7m7.1m10.7m

Prepaid Expenses

215.1k588.0k2.7m

Current Assets

5.2m8.3m8.0m13.5m

PP&E

23.1k33.0k316.0k

Goodwill

11.1m11.1m11.1m

Total Assets

16.4m19.5m19.6m25.2m

Accounts Payable

1.0m810.0k1.2m2.2m

Current Liabilities

1.3m2.2m3.9m3.6m

Long-term debt

276.0k

Total Debt

296.4k276.0k

Total Liabilities

1.4m2.4m5.3m9.7m

Common Stock

12.2k21.0k46.0k

Preferred Stock

Additional Paid-in Capital

19.6m31.6m40.6m55.1m

Retained Earnings

(4.7m)(14.5m)(26.4m)(39.6m)

Total Equity

15.0m17.1m14.3m15.6m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.1 x1.1 x1.4 x1.6 x

Moleculin Biotech Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(3.9m)(9.8m)(11.9m)(13.2m)

Depreciation and Amortization

6.2k18.0k68.0k199.0k

Accounts Payable

(41.1k)411.0k436.0k907.0k

Cash From Operating Activities

(3.8m)(7.3m)(12.2m)(17.2m)

Purchases of PP&E

(21.5k)(28.0k)(417.0k)(52.0k)

Cash From Investing Activities

(121.1k)(28.0k)(417.0k)(51.0k)

Short-term Borrowings

(469.9k)

Cash From Financing Activities

8.9m10.1m12.0m20.9m

Net Change in Cash

5.0m2.7m(580.0k)3.6m

Interest Paid

4.6k3.0k5.0k1.0k

Income Taxes Paid

19.0k

Moleculin Biotech Ratios

USDQ1, 2016

Debt/Equity

-0.9 x

Debt/Assets

2.1 x

Financial Leverage

-0.4 x